Seval, N., Roth, P., Frank, C. A., Di Paola, A., Litwin, A. H., Vander Wyk, B., Neirinckx, V., Schlossberg, E., Lawson, P., Strong, M., Schade, M. A., Nunez, J., Levin, F. R., Brady, K. T., Nunes, E. V., & Springer, S. A. (2025). Initiating Injectable Buprenorphine in People Hospitalized With Infections. JAMA Network Open, 8(5), e2513000. https://doi.org/10.1001/jamanetworkopen.2025.13000

Shulman, M., Choo, T.-H., Ohrtman, K., Pavlicova, M., Rotrosen, J., & Nunes, E. V. (2025). Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial. Drug and Alcohol Dependence, 268, 112550. https://doi.org/10.1016/j.drugalcdep.2025.112550

Shulman, M., Greiner, M. G., Tafessu, H. M., Opara, O., Ohrtman, K., Potter, K., Hefner, K., Jelstrom, E., Rosenthal, R. N., Wenzel, K., Fishman, M., Rotrosen, J., Ghitza, U. E., Nunes, E. V., & Bisaga, A. (2024). Rapid Initiation of Injection Naltrexone for Opioid Use Disorder. JAMA Network Open, 7(5), e249744. https://doi.org/10.1001/jamanetworkopen.2024.9744

Bunting, A. M., Krawczyk, N., Choo, T.-H., Pavlicova, M., McNeely, J., Tofighi, B., Rotrosen, J., Nunes, E., & Lee, J. D. (2022). Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes. Journal of Substance Abuse Treatment, 143, 108830. https://doi.org/10.1016/j.jsat.2022.108830

Roache, J. D., Pavlicova, M., Campbell, A., Choo, T., Peavy, M., Kermack, A. S., Nunes, E. V., & Rotrosen, J. (2021). Is extended release naltrexone superior to buprenorphine‐naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research, 45(12), 2569–2578. Portico. https://doi.org/10.1111/acer.14729